Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Free Cash Flow: 2023-2025

Historic Free Cash Flow for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$41.6 million.

  • Immunome's Free Cash Flow fell 16.58% to -$41.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$191.8 million, marking a year-over-year decrease of 107.19%. This contributed to the annual value of -$118.0 million for FY2024, which is 1304.54% down from last year.
  • Immunome's Free Cash Flow amounted to -$41.6 million in Q3 2025, which was up 17.25% from -$50.3 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Free Cash Flow ranged from a high of $23.9 million in Q1 2023 and a low of -$56.7 million during Q1 2025.
  • Moreover, its 3-year median value for Free Cash Flow was -$25.7 million (2024), whereas its average is -$25.0 million.
  • Data for Immunome's Free Cash Flow shows a maximum YoY crashed of 336.95% (in 2024) over the last 5 years.
  • Immunome's Free Cash Flow (Quarterly) stood at -$17.8 million in 2023, then slumped by 142.51% to -$43.2 million in 2024, then fell by 16.58% to -$41.6 million in 2025.
  • Its last three reported values are -$41.6 million in Q3 2025, -$50.3 million for Q2 2025, and -$56.7 million during Q1 2025.